Key result
Discordant cardiopulmonary function affects 34% of adult DMD patients and is not reliably predicted by genotype.
Why the study?
To determine the prevalence of discordant cardiopulmonary function among patients with Duchenne muscular dystrophy in a clinic cohort.
Observational (n=74)
No
Discordant cardiopulmonary function is common in adult patients with Duchenne muscular dystrophy, affecting approximately one-third of patients, and cannot be reliably predicted by dystrophin genotype.
Discordant cardiopulmonary function occurs in adult DMD without glucocorticoids; leaves open whether separate monitoring improves outcomes.
OBJECTIVE: To determine the prevalence of discordant cardiopulmonary function among patients with Duchenne muscular dystrophy (DMD) in our clinic. METHODS: Retrospective chart review from 1999 to 2017. INCLUSION CRITERIA: DMD patients age ≥ 18 years, alive, with discordant cardiopulmonary function. No patients received glucocorticoid therapy. Discordant cardiopulmonary function was defined as either: good heart function (EF ≥ 40%) and bad lung function (FVC < 1 L) (Group A); or, bad heart function (EF < 40%) and good lung function (FVC ≥ 1 L) (Group B). RESULTS: Among 74 eligible patients, 25 patients (34%) had discordant cardiopulmonary function (21 patients in Group A and 4 patients in Group B). Three dystrophin mutations were shared by >2 patients (nine patients with deletion of exon 44; three patients with deletion of exon 51; three patients with duplication of exon 2). Among the 15 patients with a shared genotype, eight patients (53%) had discordant cardiopulmonary function (five patients in group A, three patients in group B). Twenty-six patients had a deletion involving or distal to exon 45. Ten of these patients (38%) had discordant cardiopulmonary function (eight patients in Group A, two patients in Group B). CONCLUSION: In our cohort of DMD patients, discordant cardiopulmonary function was common (present in one-third of our patients), and the dystrophin genotype did not reliably predict a patient's cardiopulmonary phenotype. If confirmed by larger, multi-center studies, our findings have significant implications for predicting patient prognosis, evaluating DMD therapies, and designing new DMD therapies.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2018) conducted an observational in Duchenne muscular dystrophy (n=74). Dystrophin genotype was evaluated on Prevalence of discordant cardiopulmonary function. Discordant cardiopulmonary function was present in 34% of adult patients with Duchenne muscular dystrophy, and the dystrophin genotype did not reliably predict the cardiopulmonary phenotype.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: